CJC-1295 Research Timeline: What Published Studies Measured
A chronological record of peer-reviewed CJC-1295 research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Total Studies
24
Human
5
Animal
12
Evidence
L3 · Emerging Clinical Evidence
What the Research Actually Measured
Peptide research timelines are often misrepresented online. Claims about "how quickly CJC-1295works" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
Proteomic analysis showing CJC-1295 activation of the GH/IGF-1 axis produced characteristic changes in serum protein profiles including increased IGFBP-3.
Key finding: CJC-1295 produced expected GH-dependent protein profile changes, confirming genuine activation of the full GH/IGF-1 signaling cascade rather than just GH elevation.
Two randomized, placebo-controlled, double-blind ascending dose trials showing single CJC-1295 DAC injection increased GH 2-10 fold for 6+ days and IGF-1 1.5-3 fold for 9-11 days.
Key finding: CJC-1295 DAC produced dose-dependent, sustained increases in GH and IGF-1 with cumulative effects from repeated dosing — the foundational human pharmacokinetic data.
Animal study demonstrating once-daily CJC-1295 completely normalized growth in GHRH-deficient mice, proving it can substitute for endogenous GHRH signaling.
Key finding: CJC-1295 normalized body weight, body length, and organ weights in GHRH knockout mice, demonstrating full GHRH replacement capability.
Phase 2 study demonstrating CJC-1295 DAC sustained GH secretion for 7 days with single injection.
Key finding: Single 100µg injection increased mean GH concentration by 2.5-fold, sustained elevated GH for 168 hours, peak IGF-1 increase of 77% by day 7.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for CJC-1295 is L3 (Emerging Clinical Evidence): pilot human studies or limited clinical trials available. Treat each study as one data point, not a conclusion.
Frequently Asked Questions
How much human research exists on CJC-1295?
PeptideMark indexes 24 studies on CJC-1295: 5 human studies, 12 animal studies, 3 in-vitro, and 4 reviews. The current evidence level is L3 — emerging clinical evidence.
When did CJC-1295 research begin?
The earliest indexed peer-reviewed study on CJC-1295 in the PeptideMark library was published in 2000 (Neuroendocrinology). Research activity has continued through 2008.
How long do CJC-1295 clinical trials typically run?
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Is CJC-1295 research still active?
Published research activity on CJC-1295 has slowed in recent years based on indexed studies. Ongoing investigator-initiated trials may exist that are not yet indexed.
Where can I see the raw research?
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.